A Pronectin™ AXL-targeted first-in-class bispecific T cell engager (pAXLxCD3ε) for ovarian cancer.

Caterina RiilloNicoletta PoleràMaria Teresa Di MartinoGiada JuliCraig A HokansonTatjana OdinecaStefania SignorelliKatia GrilloneSerena AscrizziAntonia MancusoNicoletta StaropoliBasilio CaparelloMaria CerraGiuseppe NisticòPierosandro TagliaferriRoberto CreaDaniele CaraccioloPierfrancesco Tassone

Published in: Journal of translational medicine (2023)

pAXLxCD3ε is an active therapeutics against EOC cells providing a rational for its development as a novel agent in this still incurable disease. The preclinical validation of a first-in-class agent opens the way to the development of a new 14Fn3-based scaffold platform for the generation of innovative immune therapeutics against cancer.

Keyphrases

induced apoptosis
small molecule
papillary thyroid
cell cycle arrest
squamous cell carcinoma
tyrosine kinase
signaling pathway
cell death
oxidative stress
cell therapy
lymph node metastasis